These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 499472)

  • 1. [Experimental hypolipidemic and antiatherosclerotic activity of bisanions].
    Ryzhenkov VE; Khromov-Borisov NV; Mosina IV; Indenbom ML
    Farmakol Toksikol; 1979; 42(6):632-5. PubMed ID: 499472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hypolipidemic properties of triterpenoids].
    Vasilenko IuK; Lisevitskaia LI; Frolova LM; Parfent'eva EP; Skul'te IV
    Farmakol Toksikol; 1982; 45(5):66-70. PubMed ID: 7140959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The hypolipidemic and antiatherosclerotic action of absorbable and nonabsorbable substances in the intestines].
    Ryzhenkov VE; Chistiakova AM; Okunevich IV
    Patol Fiziol Eksp Ter; 1989; (5):16-9. PubMed ID: 2616207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hypolipidemic, hypocholesterolemic and antisclerotic action of the rotenoid glycoside amorphin].
    Kurmukov AG; Aĭzikov MI; Rasulova SA; Makhmudov OKh
    Farmakol Toksikol; 1986; 49(6):54-7. PubMed ID: 3817147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Xanthine compounds with anti-arteriosclerotic effect in rabbits].
    Dadej R
    Ann Acad Med Stetin; 1987; 33():139-54. PubMed ID: 2967649
    [No Abstract]   [Full Text] [Related]  

  • 6. [The efficacy of substances with antihypoxic action in experimental hyperlipidemia].
    Ryzhenkov VE; Remezova OV; Triufanov VF; Vasil'eva LE
    Eksp Klin Farmakol; 1992; 55(5):39-41. PubMed ID: 1305449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The angioprotector and hypolipemic activity of leukomizin in experimental atherosclerosis].
    Kirmukov AG; Aĭzikov MI; Rasulova SA; Sidiakin GP; Sham'ianov ID; Malikov VM
    Farmakol Toksikol; 1991; 54(3):35-7. PubMed ID: 1915817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The hypolipidemic and antiatherosclerotic properties of the ammonium salt of glycyrrhetic acid and of 18-dehydroglycyrrhetic acid].
    Zakirov UB; Abdullaev AKh
    Eksp Klin Farmakol; 1996; 59(5):53-5. PubMed ID: 9026213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal models for an integrated approach to the pharmacologic control of atherosclerosis.
    Day CE; Phillips WA; Schurr PE
    Artery; 1979 Feb; 5(2):90-109. PubMed ID: 120168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances in pharmacotherapy of arteriosclerosis].
    Balewska K; Witanowska A
    Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):103-7. PubMed ID: 2216947
    [No Abstract]   [Full Text] [Related]  

  • 11. [Lipid depression by etofibrate in a comparative study in rats with artificial hyperlipidemia].
    Sterner W; Schultz A
    Arzneimittelforschung; 1974 Dec; 24(12):1990-2. PubMed ID: 4480360
    [No Abstract]   [Full Text] [Related]  

  • 12. Potential hypolipidemic agents. XVII. Synthesis and plasma lipid-lowering properties of compounds related to ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate and ethyl 2-(4-chlorophenoxy)-2-methylpropionate.
    Högberg T; Bondesson G; Stjernström NE
    Acta Pharm Suec; 1977; 14(2):149-60. PubMed ID: 906832
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypolipidemic activity of Indan--1--acetic acids.
    Adak M; Gupta JK
    Nepal Med Coll J; 2006 Mar; 8(1):22-6. PubMed ID: 16827085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of eicosapentaenoic acid on lipid metabolism in rabbits with experimental atherosclerosis].
    Ren LKh; Vasil'ev AV; Tutel'ian VA
    Vopr Pitan; 1988; (6):40-3. PubMed ID: 2852878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current trends in the therapy of arteriosclerotic disease].
    Toscano S
    G Clin Med; 1974 Jan; 55(1):27-39. PubMed ID: 4369524
    [No Abstract]   [Full Text] [Related]  

  • 16. Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
    Badimón JJ; Padró T; Cánovas M; Vidal M; Villaverde CA
    Methods Find Exp Clin Pharmacol; 1983 Nov; 5(9):613-7. PubMed ID: 6668971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clofibrate controlled trial of gemfibrozil in the treatment of hyperlipidaemias.
    Tuomilehto J; Salonen J; Kuuisto P; Virtamo J; Manninen V; Mälkönen M
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):38-40. PubMed ID: 798195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characteristics of glyciram and glycirenate in experimental arteriosclerosis].
    Skul'te IV; Vasilenko IuK; Ponomarev VD
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1982; (10):56-60. PubMed ID: 7171653
    [No Abstract]   [Full Text] [Related]  

  • 19. [The possible means for the pharmacological correction of lipid metabolic disorders in atherosclerosis].
    Piskun RP; Pentiuk AA; Serkova VK; Polesia TL; Savitskaia EA
    Eksp Klin Farmakol; 1997; 60(2):78-85. PubMed ID: 9206580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of L-DOPA on the development of experimental hyperlipidemia and atherosclerosis].
    Mosina IV; Ryzhenkov VE
    Biull Eksp Biol Med; 1981 Mar; 91(3):270-1. PubMed ID: 7248493
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.